Here are the DEF 14A proxy statements from Interpace Biosciences New (IDXG) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow IDXG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IDXG filings page.
Interpace Biosciences is asking stockholders at its virtual August 20, 2026 annual meeting to approve several significant governance and capital structure changes. The company proposes an amended and restated charter that would double authorized common shares to 200,000,000, declassify the board so all directors stand for annual election, remove 75% supermajority voting requirements, expand director and officer liability protection, adopt exclusive forum clauses, and waive the corporate opportunity doctrine for directors and officers.
Stockholders are also being asked to grant the board discretionary authority to implement a reverse stock split between 1‑for‑2 and 1‑for‑10, mainly to support a potential Nasdaq uplisting from OTC trading. Additional items include approval of a new 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan, director elections structured differently depending on whether the new charter passes, an advisory say‑on‑pay vote, and ratification of EisnerAmper LLP as auditor. There were 27,700,904 common shares outstanding as of the June 29, 2026 record date, and two investors control about 84% of those shares.